Scholarlink

<p>The EphA2 receptor tyrosine kinase has been implicated in cellular transformation and malignancy and is frequently overexpressed in a wide range of cancers, including those of the breast, bladder, esophagus, pancreas, prostate, lung, and colon. Due to its oncogenic relevance, EphA2 represents an attractive molecular target for precision imaging and therapy. This study reports the development of a novel <sup>64</sup>Cu-labeled peptide, TYPE7, for PET imaging of EphA2 expressing tumors. TYPE7 is a soluble peptide that integrates into the cell membrane where it targets EphA2 to induce receptor oligomerization and phosphorylation. Here, we describe the synthesis and characterization of [<sup>64</sup>Cu]Cu-DOTA-TYPE7 and evaluate its in vitro binding properties and in vivo performance in an EphA2+ tumor model. [<sup>64</sup>Cu]Cu-DOTA-TYPE7 was synthesized under mild reaction conditions, exhibiting radiochemical yields &gt; 95%. The results obtained from the cellular binding assays using PANC-1 (EphA2 + ) and HEK-293T (EphA2-) cell lines support EphA2 specific binding. PET imaging enabled clear visualization of EphA2+ tumors, with peak uptake observed 4 h post injection, consistent with ex vivo biodistribution results. Together, these findings establish [<sup>64</sup>Cu]Cu-DOTA-TYPE7 as a promising PET tracer for imaging EphA2-expressing diseases and provides a foundation for future development of EphA2-targeted theranostic applications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

[64Cu]Cu-DOTA-TYPE7: a targeted PET radiotracer for imaging EphA2+ tumors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月4日

查看全文
  • Alexis M. Sanwick,
  • Daiane S. Alves,
  • Katherine N. Haugh,
  • Francisco N. Barrera,
  • Ivis F. Chaple

摘要

The EphA2 receptor tyrosine kinase has been implicated in cellular transformation and malignancy and is frequently overexpressed in a wide range of cancers, including those of the breast, bladder, esophagus, pancreas, prostate, lung, and colon. Due to its oncogenic relevance, EphA2 represents an attractive molecular target for precision imaging and therapy. This study reports the development of a novel 64Cu-labeled peptide, TYPE7, for PET imaging of EphA2 expressing tumors. TYPE7 is a soluble peptide that integrates into the cell membrane where it targets EphA2 to induce receptor oligomerization and phosphorylation. Here, we describe the synthesis and characterization of [64Cu]Cu-DOTA-TYPE7 and evaluate its in vitro binding properties and in vivo performance in an EphA2+ tumor model. [64Cu]Cu-DOTA-TYPE7 was synthesized under mild reaction conditions, exhibiting radiochemical yields > 95%. The results obtained from the cellular binding assays using PANC-1 (EphA2 + ) and HEK-293T (EphA2-) cell lines support EphA2 specific binding. PET imaging enabled clear visualization of EphA2+ tumors, with peak uptake observed 4 h post injection, consistent with ex vivo biodistribution results. Together, these findings establish [64Cu]Cu-DOTA-TYPE7 as a promising PET tracer for imaging EphA2-expressing diseases and provides a foundation for future development of EphA2-targeted theranostic applications.